SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
VNDA ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Vanda Pharmaceuticals Inc. Shareholders Who Lost Money
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Levi & Korsinsky Reminds Vanda Pharmaceuticals Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws – VNDA
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Shareholders That Lost Money on Vanda Pharmaceuticals Inc. (VNDA) Should Contact Levi & Korsinsky About Securities Fraud Investigation - VNDA
NEW YORK, NY / ACCESSWIRE / September 27, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Vanda Pharmaceuticals Inc. Being Investigated on Behalf of Vanda Pharmaceuticals Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / September 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
ATTENTION VNDA SHAREHOLDERS: Investors who lost money on Vanda Pharmaceuticals Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / September 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Levi & Korsinsky Investigates Possible Securities Fraud Violations by Vanda Pharmaceuticals Inc. (VNDA)
NEW YORK, NY / ACCESSWIRE / September 24, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Vanda Pharmaceuticals Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - VNDA
NEW YORK, NY / ACCESSWIRE / September 23, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
VNDA Stock Down as FDA Rejects NDA for Tradipitant in Gastroparesis
The FDA issues a complete response letter to Vanda's new drug application for tradipitant for treating symptoms in gastroparesis.
Vanda Pharmaceuticals Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details - VNDA
NEW YORK, NY / ACCESSWIRE / September 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vanda Pharmaceuticals Inc. ("Vanda Pharmaceuticals Inc.") (NASDAQ:VNDA) concerning possible violations of federal securities laws. Vanda issued a press release disclosing that "[o]n September 18, 2024, the U.S. Food and Drug Administration (FDA) declined to approve Vanda's New Drug Application (NDA) of tradipitant for the treatment of symptoms in gastroparesis, providing Vanda with a Complete Response Letter (CRL).
Why Vanda Pharmaceuticals Stock Sank by Nearly 6% Today
The biotech had discouraging news to report about one of its pipeline drugs. The FDA declined to approve its application.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
